Previous 10 | Next 10 |
Icon ( NASDAQ: ICLR ) is scheduled to announce Q2 earnings results on Wednesday, July 27th, after market close. The consensus EPS Estimate is $2.79 (+31.6% Y/Y) and the consensus Revenue Estimate is $1.93B (+121.5% Y/Y). Over the last 2 years, ICLR has beaten EPS est...
West Pharmaceutical Services has performed extraordinarily well in recent years. The future of the enterprise looks bright and the company will likely continue to fare well in the years to come. But given how pricey shares are today, buying it won't make sense to a lot of investor...
BAMCO’s 13F portfolio value decreased from $47.14B to $40.75B this quarter. Ron Baron increased Spotify and Shopify while reducing Alphabet and Amazon.com. Their top five positions are at ~29% of the overall portfolio. For further details see: Tracking Ron Baron's...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced that it will release its financial results for the second quarter 2022 after the market closes on Wednesday, July 27, 2022. The company will h...
Citing the recent challenges in the patient enrollment, the pharmacy chain operator Walgreens Boots Alliance (NASDAQ:WBA) announced the launch of its clinical trial business on Thursday to expedite the drug development process. Arguing that COVID-19 has exacerbated the difficulties in patient...
Waters Corporation has followed the broader market lower, even as the company shows some attractive financial results. Long term, the picture for the business will likely be favorable, but this doesn't change the fact that there are more appealing opportunities to be had. This is ...
ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022, at 7.00am ET. It was also annou...
ICON kick starts the first half of 2022 with a string of prestigious industry awards recognising healthcare intelligence work and staff, as independently judged by peers worldwide ICON plc , (NASDAQ: ICLR) a global provider of drug and device development and commercialis...
PerkinElmer has experienced significant growth over the past few years, admittedly with some of it being temporary because of the pandemic. This year should be weaker than last year was, but the overall fundamental condition for the enterprise is solid. Add in that shares look att...
Polen Capital is a high-conviction growth investment manager. We scour the globe in search of the highest quality, sustainable companies to invest in. Over the first quarter of 2022, the Polen International Growth Composite Portfolio returned -13.94% gross and -14.17% net of fees, res...
News, Short Squeeze, Breakout and More Instantly...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, July 24, 2024. The company will hold a conference call and webcas...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 1:30pm ET. Any changes to this event and links...
2024-05-31 07:00:07 ET David Windley from Jefferies issued a price target of $390.00 for ICLR on 2024-05-31 05:48:00. The adjusted price target was set to $390.00. At the time of the announcement, ICLR was trading at $322.92. The overall price target consensus is at $265...